High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis

Thrombosis and Haemostasis

Volumn 105, Issue 5, 2011, Pages 883-891

  Katsaros, Katharina M ^a,c   Wiesbauer, Franz ^a   Speidl, Walter S ^a   Kastl, Stefan P ^a,c   Huber, Kurt ^b   Zorn, Gerlinde ^a   Niessner, Alexander ^a   Glogar, Dietmar ^a   Maurer, Gerald ^a   Wojta, Johann ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Inflammation; Restenosis; Stent

Indexed keywords

C REACTIVE PROTEIN; FAS ANTIGEN; FAS LIGAND; FIBRINOGEN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; ANGIOPLASTY; ANTIGENS, CD95; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; FAS LIGAND PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; STENTS;

EID: 79955760413     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-09-0566     Document Type: Article

References (44)

1. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218-224.
2. Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007; 50: 2029-2036.
3. Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005; 45: 308-311.
4. Simonton CA, Brodie B, Cheek B, et al. Comparative clinical outcomes of paclitaxel-and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group. J Am Coll Cardiol 2007; 50: 1214-1222.
5. Cosgrave J, Melzi G, Corbett S, et al. Comparable clinical outcomes with paclitaxel-and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 2007; 49: 2320-2328.
6. Li JJ, Nie SP, Zhang CY, et al. Is inflammation a contributor for coronary stent restenosis? Med Hypotheses 2007; 68: 945-951.
7. Katsaros KM, Speidl WS, Kastl SP, et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 2008; 6: 508-513.
8. Katsaros KM, Kastl SP, Zorn G, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and-9. JACC Cardiovasc Interv 2010; 3: 90-97.
9. Vivanco F, Martin-Ventura JL, Duran MC, et al. Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res 2005; 4: 1181-1191.
10. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006; 47 (8 Suppl): C19-31.
11. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
12. Blanco-Colio LM, Martin-Ventura JL, Vivanco F, et al. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res 2006; 72: 18-29.
13. Mano T, Luo Z, Suhara T, et al. Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions. Hum Gene Ther 2000; 11: 1625-1635.
14. Jiang C, Yang YF, Cheng SH. Fas ligand gene therapy for vascular intimal hyperplasia. Curr Gene Ther 2004; 4: 33-39.
15. Luo Z, Garron T, Palasis M, et al. Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35. Hum Gene Ther 2001; 12: 2191-2202.
16. Luo Z, Sata M, Nguyen T, et al. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 1999; 99: 1776-1779.
17. Sata M, Perlman H, Muruve DA, et al. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci USA 1998; 95: 1213-1217.
18. Matter CM, Chadjichristos CE, Meier P, et al. Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation. Circulation 2006; 113: 1879-1887.
19. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-444.
20. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
21. Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4: 415-420.
22. Chan SW, Hegyi L, Scott S, et al. Sensitivity to Fas-mediated apoptosis is determined below receptor level in human vascular smooth muscle cells. Circ Res 2000; 86: 1038-1046.
23. Niessner A, Hohensinner PJ, Rychli K, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009; 30: 789-796.
24. Boos CJ, Balakrishnan B, Blann AD, et al. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 2008; 6: 1841-1850.
25. Isner JM, Kearney M, Bortman S, et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703-2711.
26. Kastrati A, Schomig A, Elezi S, et al. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999; 100: 1285-1290.
27. Dupont WD, Plummer WD, Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11: 116-128.
28. Rothman K, Greenland S. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 1998.
29. Xu YG, Zhou SH, Li YG, et al. The mechanism underlying vascular smooth muscle cell apoptosis induced by atorvastatin may be mainly associated with down-regulation of survivin expression. Cardiovasc Drugs Ther 2007; 21: 145-153.
30. Blanco-Colio LM, Martin-Ventura JL, Sol JM, et al. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 2004; 43: 1188-1194.
31. Perlman H, Maillard L, Krasinski K, et al. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 1997; 95: 981-987.
32. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res 2000; 87: 184-188.
33. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
34. Sata M, Suhara T, Walsh K. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol 2000; 20: 309-316.
35. Dupont PJ, Warrens AN. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology 2007; 120: 133-139.
36. Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-2050.
37. Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36.
38. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
39. Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 1999; 162: 480-485.
40. Kiener PA, Davis PM, Rankin BM, et al. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997; 159: 1594-1598.
41. Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429-440.
42. Imanishi T, Han DK, Hofstra L, et al. Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from monocytes/macrophage. Atherosclerosis 2002; 161: 143-151.
43. Papoff G, Cascino I, Eramo A, et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622-4630.
44. Proussakova OV, Rabaya NA, Moshnikova AB, et al. Oligomerization of soluble Fas antigen induces its cytotoxicity. J Biol Chem 2003; 278: 36236-36241.